Hikma Pharmaceuticals (LON:HIK) Price Target Cut to GBX 2,000 by Analysts at Deutsche Bank Aktiengesellschaft

Hikma Pharmaceuticals (LON:HIK) had its price objective dropped by equities research analysts at Deutsche Bank Aktiengesellschaft from GBX 2,050 to GBX 2,000 in a research note issued to investors on Friday, Digital Look reports. The brokerage presently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft‘s price target would indicate a potential upside of 22.93% from the stock’s previous close.

A number of other brokerages have also recently commented on HIK. Berenberg Bank increased their price target on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Citigroup lifted their price target on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Finally, Jefferies Financial Group restated a “buy” rating and issued a GBX 2,025 price objective on shares of Hikma Pharmaceuticals in a report on Thursday. Six research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, Hikma Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of GBX 2,094.17.

Hikma Pharmaceuticals Stock Performance

LON:HIK opened at GBX 1,627 on Friday. The business has a 50 day moving average of GBX 1,627.45 and a 200 day moving average of GBX 1,508.30. The company has a market capitalization of £3.37 billion, a price-to-earnings ratio of 9.24, a PEG ratio of 2.38 and a beta of 0.65. Hikma Pharmaceuticals has a 1-year low of GBX 1,187 and a 1-year high of GBX 1,762. The company has a debt-to-equity ratio of 77.57, a current ratio of 1.98 and a quick ratio of 1.27.

Insider Activity

In related news, insider Tobias Hestler acquired 7,500 shares of Hikma Pharmaceuticals stock in a transaction dated Monday, August 10th. The shares were purchased at an average cost of GBX 1,648 per share, with a total value of £123,600. Company insiders own 22.26% of the company’s stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.